923 related articles for article (PubMed ID: 9476320)
1. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
2. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
3. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
4. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
5. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012600. PubMed ID: 28295158
[TBL] [Abstract][Full Text] [Related]
6. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
7. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials.
Perni SC; Predanic M; Kalish RB; Chervenak FA; Chasen ST
Am J Obstet Gynecol; 2006 Jan; 194(1):127-30. PubMed ID: 16389021
[TBL] [Abstract][Full Text] [Related]
9. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
10. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
11. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
[TBL] [Abstract][Full Text] [Related]
12. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
[TBL] [Abstract][Full Text] [Related]
13. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
Thilaganathan B; Slack A; Wathen NC
Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
[TBL] [Abstract][Full Text] [Related]
14. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
15. First-trimester screening for trisomies 21 and 18.
Wapner R; Thom E; Simpson JL; Pergament E; Silver R; Filkins K; Platt L; Mahoney M; Johnson A; Hogge WA; Wilson RD; Mohide P; Hershey D; Krantz D; Zachary J; Snijders R; Greene N; Sabbagha R; MacGregor S; Hill L; Gagnon A; Hallahan T; Jackson L;
N Engl J Med; 2003 Oct; 349(15):1405-13. PubMed ID: 14534333
[TBL] [Abstract][Full Text] [Related]
16. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
Krantz DA; Hallahan TW; Orlandi F; Buchanan P; Larsen JW; Macri JN
Obstet Gynecol; 2000 Aug; 96(2):207-13. PubMed ID: 10908764
[TBL] [Abstract][Full Text] [Related]
17. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
18. First-trimester or second-trimester screening, or both, for Down's syndrome.
Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
[TBL] [Abstract][Full Text] [Related]
19. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome.
Wald NJ; Hackshaw AK
Prenat Diagn; 1997 Sep; 17(9):821-9. PubMed ID: 9316126
[TBL] [Abstract][Full Text] [Related]
20. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A.
Spencer K
BJOG; 2001 Oct; 108(10):1043-6. PubMed ID: 11702835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
